Drug intelligence / Profile preview

SPH7485

Development stage: Phase 1
Modality: Small Molecules
Administration: Oral

Overview

SPH7485 is an investigational small molecule drug currently being evaluated for the treatment of advanced solid tumors. Its mechanism of action has not been disclosed or remains unknown. The drug is administered orally and, as of now, does not have any FDA designation. Clinical studies are ongoing to assess its efficacy and safety in patients with advanced solid tumors.

Beyond the preview

Go deeper on SPH7485.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPH7485.

Explore the full profile